argenx to acquire Forte Biosciences for $2.2bn
Dutch-Belgian immunology group argenx SE has entered a definitive agreement to acquire US-based biopharma group Forte Biosciences in an all-cash transaction valued at approximately $2.2bn. This deal, the largest in the history of the Euronext-listed firm, marks a significant pivot as argenx seeks to diversify its portfolio beyond its flagship blockbuster treatment, Vyvgart. Under the terms of the agreement, argenx…
Samsung Biologics Strikes €1.57bn Deal for PolyPeptide
Samsung Biologics, a leading South Korean CDMO that provides integrated services from discovery to commercial production, has entered into a definitive agreement to acquire Swiss listed PolyPeptide Group in a deal valuing the company at CHF 1.46bn (€1.57bn). PolyPeptide is a Swiss based specialist contract manufacturer of peptide based active pharmaceutical ingredients used by major pharmaceutical and biotechnology firms globally.…
G Square closes £500m Pharmacy2U continuation fund
Private equity specialist G Square Capital has closed a £500 million single-asset continuation fund for Pharmacy2U, the UK’s largest online pharmacy. This transaction represents one of the most notable GP-led secondary deals in the European health-tech sector. Coller Capital acted as the sole lead investor, partnering with a syndicate of blue-chip institutional investors, reinvesting shareholders, and Pharmacy2U’s management team. Since…
Novartis buys Myricx Bio in $1.5bn deal
Swiss drug and health care company Novartis has acquired London based biotech Myricx Bio in a deal valued at up to $1.5bn Announced on July 6, the deal comprises a substantial $1.1bn upfront cash payment and $400 million in potential milestones. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals. Myricx Bio…
Ipsen to acquire Kartos Therapeutics for up to $1.75bn
Global biopharmaceutical company Ipsen is to acquire California-based clinical-stage biopharmaceutical company Kartos Therapeutics in a transaction valued at up to $1.75bn. The deal involves an upfront cash payment of $450m, with a further $1.3bn tied to the achievement of regulatory and commercial milestones. This transaction is expected to close in the third quarter of 2026 and highlights Ipsen’s continued focus…
Ipsen strikes up to €700m deal for Swiss biotech firm
Paris-based listed global biopharmaceutical company Ipsen SA has acquired Swiss biotechnology firm Memo Therapeutics AG in a deal that could exceed €700m. This transaction will integrate a first-in-class asset into Ipsen’s clinical pipeline as it seeks to address high unmet medical needs in transplantation, and highlights a growing trend of major European pharmaceutical companies securing specialised platform technologies to drive…
AbbVie to acquire Apogee for $10.9bn
Listed US-based global biopharmaceutical company AbbVie has agreed to acquire clinical stage biotechnology firm Apogee Therapeutics in an all cash transaction valued at approximately $10.9bn. This purchase price represents a premium of approximately 49 per cent to the closing price of Apogee shares on June 18, 2026. The transaction, which has been unanimously approved by the boards of both companies,…
Motion Equity Partners acquires majority stake in Polaris
French private equity firm Motion Equity Partners has acquired a majority stake in Polaris, a Brittany-based biotechnology specialist renowned for its high-concentration, microalgae-derived omega-3 nutritional lipids. The transaction marks the exit of Demea Agro. Historical institutional backing remains strong as previous shareholders, including Cerea Partners, Seventure Partners, and Picama, have reinvested alongside the new majority owners to support the company…
GSK bolsters oncology portfolio with $10.6bn Nuvalent
GSK is to acquire Boston-based clinical-stage oncology specialist Nuvalent for an equity value of approximately $10.6bn. This marks the British pharmaceutical giant’s largest transaction in over a decade. GSK will pay 124 dollars per share in cash for all outstanding Nuvalent common stock – a 40 per cent premium to Nuvalent’s previous closing stock price. The tender offer is scheduled…
CordenPharma makes peptide play with AmbioPharm acquisition
Swiss contract development and manufacturing organisation CordenPharma is buying the US-headquartered peptide specialist AmbioPharm. The transaction will significantly bolster the global peptide production capacity of CordenPharma, which is owned by the private equity firm Astorg. While the financial details of the deal remain undisclosed, the acquisition marks a major expansion for CordenPharma into the complex peptide active pharmaceutical ingredient market.…